临床试验

SIMPLAAFY Clinical Trial

NCT：NCT06521463 · ACTIVE_NOT_RECRUITING

NCT编号NCT06521463

状态ACTIVE_NOT_RECRUITING

开始日期2024-10-01

SponsorBoston Scientific Corporation (INDUSTRY)

First posted2024-07-26

Last updated2026-09-11

简要摘要

The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。